Developing Transformative Therapies for Patients with Fibrotic Disease

Arxx Therapeutics develops a first-in-class monoclonal antibody with a unique mechanism of action targeting non-resolving tissue fibrosis

Our Purpose

We are committed to improve and extend the lives of people suffering from fibrotic disease. We use science-driven innovation to develop therapies with the potential to transform the management of fibrosis and help the many patients poorly served by current therapeutic options.

Science

We are leveraging more than 30 years of research by our scientific co-founders uncovering the pathobiology of S100A4; a Damage Associated Molecular Pattern protein upregulated upon stress or injury allowing cells to sense and react to danger. In chronically diseased tissue, S100A4 is inappropriately activated which leads to persistent inflammation and non-resolving tissue fibrosis. Our lead candidate AX-202 is a high-affinity monoclonal antibody neutralizing the bioactivity of S100A4. AX-202 confers targeted, upstream and disease-specific modulation of the self-sustaining feedback loop driving persistent fibrogenesis.
Find out more

Pipeline

Discovery
Optimization
PoC
Preclinical
Phase 1
Phase 2
Phase 3
Systemic Sclerosis
AX-202
Lorem Ipsum Dolor
85%
Our pipeline in more detail

Pipeline

Candidate
Discovery
Optimization
PoC
Preclinical
Phase 1
Phase 2
Phase 3
Systemic Sclerosis
AX-202
Lorem Ipsum Dolor
85%
Our pipeline in more detail

Pipeline

Candidate
Discovery
Optimization
PoC
Preclinical
Phase 1
Phase 2
Phase 3
Systemic Sclerosis
AX-202
Lorem Ipsum Dolor
85%
Our pipeline in more detail

About Us

Arxx Therapeutics is a Scandinavian biotechnology company founded by scientists and drug developers dedicated to help the large number of patients whose lives are impacted by fibrotic disease.
Find out more

Get in touch

    We are dedicated to developing transformative therapies for patients with fibrotic disease.
    We believe that AX-202 has the potential to transform how fibrosis is treated and help many patients poorly served by current therapeutic options.
    Arxx Therapeutics
    in Norway: Gaustadalléen 21, 0349 Oslo
    in Denmark: Symbion Science Park, Fruebjergvej 3, 2100 Copenhagen 
    © 2021 Arxx Therapeutics. All rights reserved. | Privacy Policy